Illumina, Inc. - Common Stock (ILMN)
Frequently Asked Questions About Illumina, Inc. - Common Stock (ILMN)
How does Illumina contribute to cancer research?
Illumina contributes to cancer research through its advanced sequencing technologies and genomic analysis solutions, which help researchers identify mutations and understand the genetic basis of various cancers. By enabling comprehensive genomic profiling, Illumina's products support the development of targeted therapies and personalized treatment plans for cancer patients.
How does Illumina support research and development?
Illumina supports research and development through various programs, including grants, partnerships with academic institutions, and collaborations with industry leaders. The company also invests in training and educational resources to empower researchers in leveraging its technologies for groundbreaking studies and discoveries.
How does Illumina use artificial intelligence in its operations?
Illumina utilizes artificial intelligence (AI) across various facets of its operations, from data analysis and interpretation in genomic studies to enhancing workflow efficiencies in sequencing laboratories. AI helps in managing large datasets, improving the accuracy of genomic predictions, and streamlining research processes.
How has Illumina grown since its inception?
Since its inception, Illumina has experienced significant growth both in terms of revenue and technology advancement. The company has continuously innovated its sequencing platforms and expanded its product portfolio to meet the evolving needs of researchers and clinicians around the globe. Through strategic acquisitions and partnerships, Illumina has solidified its position as a leader in the genomics field.
Is Illumina publicly traded?
Yes, Illumina, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol ILMN. The company went public in 2000, and its stock has been a significant player in the biotech sector, reflecting its growth and influence within the life sciences industry.
What are Illumina's future growth prospects?
Illumina's future growth prospects appear promising due to the increasing demand for genomic research and personalized medicine. As the field of genomics continues to evolve, Illumina is well-positioned to drive innovation, expand its market presence, and contribute to advancements in healthcare and scientific research.
What are next-generation sequencing (NGS) technologies?
Next-generation sequencing (NGS) technologies are advanced methods that allow for rapid sequencing of DNA and RNA. Unlike traditional methods, NGS enables the simultaneous processing of millions of segments of genes, making it a powerful tool for genomic analysis, research, and clinical diagnostics.
What are the ethical considerations in genomics that Illumina addresses?
Illumina acknowledges the ethical considerations in genomics, such as privacy, consent, and the implications of genetic information. The company actively engages in discussions regarding ethical practices in genetic testing and data management, promoting transparency and responsible use of genomic data to build public trust in these technologies.
What does Illumina, Inc. do?
Illumina, Inc. is a biotechnology company that develops and manufactures systems for the analysis of genetic variation and function. It specializes in providing next-generation sequencing (NGS) and array-based solutions that empower researchers and clinicians to understand genetic information in a comprehensive manner, improving health outcomes and advancing genomic research.
What is Illumina's approach to global health?
Illumina takes a proactive approach to global health by making its technologies accessible worldwide, particularly in underserved regions. The company engages in partnerships and initiatives aimed at addressing global health challenges, facilitating research and improvements in healthcare through genomic solutions.
What is Illumina's commitment to sustainability?
Illumina is committed to sustainability and aims to minimize its environmental footprint through various initiatives, including responsible sourcing, reducing waste, and enhancing energy efficiency in its operations. The company believes that sustainable practices contribute to long-term success and benefit society as a whole.
What is Illumina's mission statement?
Illumina's mission is to unlock the power of the genome to benefit humanity. The company aims to provide innovative sequencing and array-based solutions that advance genomic research and enable the use of genetic insights to improve health and quality of life across the globe.
What is Illumina's role in personalized medicine?
Illumina plays a pivotal role in personalized medicine by providing technologies that facilitate the understanding of an individual's genetic makeup. This information can be used to tailor treatments based on one's unique genetic profile, thus improving healthcare outcomes and advancing the development of precision therapies that are more effective for patients.
What is the Illumina Foundation?
The Illumina Foundation is a nonprofit organization established by Illumina to support initiatives in global health, education, and research. The foundation focuses on harnessing the power of genomics to address social and health disparities and enhance the understanding of genetic information for diverse populations.
What is the significance of Illumina's developer's ecosystem?
Illumina's developer ecosystem provides researchers and developers with the tools and support they need to build applications and analyses around Illumina’s sequencing data. This ecosystem fosters collaboration, encourages innovation, and allows for the development of new methods and technologies that extend the capabilities of genomic research.
What markets does Illumina serve?
Illumina serves a diverse range of markets, including academic and governmental research institutions, clinical laboratories, pharmaceutical companies, and agricultural companies. By offering tools and solutions tailored to each market, Illumina helps to drive advancements in genomics across various fields, from healthcare to agriculture.
What products does Illumina offer?
Illumina offers a wide range of products, including next-generation sequencing platforms, genetic analysis systems, and comprehensive bioinformatics solutions. These tools are designed for applications in various fields such as clinical genomics, oncology, reproductive health, and agriculture, helping to decode the human genome and facilitate personalized medicine.
When was Illumina founded?
Illumina was founded in 1998, with the aim of revolutionizing genetic research through innovative technology. Since then, it has grown to become a leader in the field of genomics, significantly impacting the landscape of personalized medicine and genomic research.
Where is Illumina headquartered?
Illumina is headquartered in San Diego, California. This strategic location places the company in a hub of biotechnology and innovation, allowing it to collaborate with leading researchers and institutions in the life sciences sector.
What is the current price of Illumina, Inc. - Common Stock?
The current price of Illumina, Inc. - Common Stock is 81.88
When was Illumina, Inc. - Common Stock last traded?
The last trade of Illumina, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Illumina, Inc. - Common Stock?
The market capitalization of Illumina, Inc. - Common Stock is 12.99B
How many shares of Illumina, Inc. - Common Stock are outstanding?
Illumina, Inc. - Common Stock has 158.60M shares outstanding.